Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renzo Galanello

Showing results (91-100 of 113) with videos related to

Pageof 12
Sort By:
Blood|May 17, 2012
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled studyAli T Taher, John Porter, Vip Viprakasit, et al.
Annals of Hematology|June 19, 2013
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA studyAli T Taher, John B Porter, Vip Viprakasit, et al.
American Journal of Hematology|April 5, 2013
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patientsAli T Taher, John B Porter, Vip Viprakasit, et al.
Haematologica|October 5, 2006
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia majorRenzo Galanello, Antonio Piga, Gian Luca Forni, et al.
Haematologica|July 5, 2006
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadAntonio Piga, Renzo Galanello, Gian Luca Forni, et al.
Circulation|June 19, 2013
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart AssociationDudley J Pennell, James E Udelson, Andrew E Arai, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|March 28, 2017
Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemiaPaul Kirk, Mary Sheppard, John-Paul Carpenter, et al.
Blood|January 19, 2012
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overloadEllis J Neufeld, Renzo Galanello, Vip Viprakasit, et al.
Revista Brasileira De Hematologia E Hemoterapia|January 31, 2014
Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusionMonica Pinheiro de Almeida Veríssimo, Sandra Regina Loggetto, Antonio Fabron Junior, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|July 8, 2011
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overloadGillian C Smith, Francisco Alpendurada, John Paul Carpenter, et al.
Pageof 12

Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
Blood|May 17, 2012
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled studyAli T Taher, John Porter, Vip Viprakasit, et al.
Annals of Hematology|June 19, 2013
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA studyAli T Taher, John B Porter, Vip Viprakasit, et al.
American Journal of Hematology|April 5, 2013
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patientsAli T Taher, John B Porter, Vip Viprakasit, et al.
Haematologica|October 5, 2006
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia majorRenzo Galanello, Antonio Piga, Gian Luca Forni, et al.
Haematologica|July 5, 2006
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadAntonio Piga, Renzo Galanello, Gian Luca Forni, et al.
Circulation|June 19, 2013
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart AssociationDudley J Pennell, James E Udelson, Andrew E Arai, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|March 28, 2017
Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemiaPaul Kirk, Mary Sheppard, John-Paul Carpenter, et al.
Blood|January 19, 2012
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overloadEllis J Neufeld, Renzo Galanello, Vip Viprakasit, et al.
Revista Brasileira De Hematologia E Hemoterapia|January 31, 2014
Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusionMonica Pinheiro de Almeida Veríssimo, Sandra Regina Loggetto, Antonio Fabron Junior, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|July 8, 2011
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overloadGillian C Smith, Francisco Alpendurada, John Paul Carpenter, et al.
Pageof 12